Palisade bio reports second quarter 2024 financial results and provides business update

– continued progress toward commencement of phase 1 human clinical study of lead product candidate, pali-2108, for the treatment of ulcerative colitis (uc) before year end

PALI Ratings Summary

PALI Quant Ranking